Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme

[1]  C. Hadjipanayis,et al.  EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. , 2010, Cancer research.

[2]  Peter Wust,et al.  Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. , 2010, The Lancet. Oncology.

[3]  Jenghwa Chang,et al.  Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. , 2009, International journal of radiation oncology, biology, physics.

[4]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[5]  R. Labianca,et al.  Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) , 2009, Cancer Chemotherapy and Pharmacology.

[6]  Karl-Titus Hoffmann,et al.  Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles. , 2009, Biomaterials.

[7]  L. Buie,et al.  Bevacizumab: A Treatment Option for Recurrent Glioblastoma Multiforme , 2008, The Annals of pharmacotherapy.

[8]  M. Mehta,et al.  Improvement, Clinical Course, and Quality of Life After Palliative Radiotherapy for Recurrent Glioblastoma , 2008, American journal of clinical oncology.

[9]  G. Broggi,et al.  Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival? , 2008, Journal of Neuro-Oncology.

[10]  R. Warnick,et al.  Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme. , 2008, Journal of neurosurgery.

[11]  Elizabeth Eisenhauer,et al.  Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. , 2008, The Lancet. Oncology.

[12]  Peter Wust,et al.  Thermotherapy of prostate cancer using magnetic nanoparticles: feasibility, imaging, and three-dimensional temperature distribution. , 2007, European urology.

[13]  G. Reifenberger,et al.  Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P Wust,et al.  Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: Results of a prospective phase I trial , 2007, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[15]  A. Brandes,et al.  Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) , 2006, British Journal of Cancer.

[16]  Hans-Joachim Schwarzmaier,et al.  MR-guided laser-induced interstitial thermotherapy of recurrent glioblastoma multiforme: preliminary results in 16 patients. , 2006, European journal of radiology.

[17]  F. Zanella,et al.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. , 2006, The Lancet. Oncology.

[18]  S. Loening,et al.  Thermotherapy using magnetic nanoparticles combined with external radiation in an orthotopic rat model of prostate cancer , 2006, The Prostate.

[19]  Peter Wust,et al.  Intracranial Thermotherapy using Magnetic Nanoparticles Combined with External Beam Radiotherapy: Results of a Feasibility Study on Patients with Glioblastoma Multiforme , 2006, Journal of Neuro-Oncology.

[20]  Roland Felix,et al.  The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma , 2006, Journal of Neuro-Oncology.

[21]  C. Rhee,et al.  ACNU–cisplatin Continuous Infusion Chemotherapy as Salvage Therapy for Recurrent Glioblastomas: Phase II Study , 2005, Journal of Neuro-Oncology.

[22]  A. Olivi,et al.  Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy. , 2005, International journal of radiation oncology, biology, physics.

[23]  K. Bratengeier,et al.  Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma , 2005, BMC Cancer.

[24]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[25]  J. Debus,et al.  Stereotactically Guided Fractionated Re-irradiation in Recurrent Glioblastoma Multiforme , 2005, Journal of Neuro-Oncology.

[26]  Peter Wust,et al.  Description and characterization of the novel hyperthermia- and thermoablation-system MFH 300F for clinical magnetic fluid hyperthermia. , 2004, Medical physics.

[27]  Susan M. Chang,et al.  Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. , 2004, Neuro-oncology.

[28]  Susan M. Chang,et al.  Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. , 2004, Journal of neurosurgery.

[29]  Allan H Friedman,et al.  Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Raymond Sawaya,et al.  Extent of Resection in Malignant Gliomas: a Critical Summary , 2004, Journal of Neuro-Oncology.

[31]  U. Bogdahn,et al.  Salvage therapy in patients with glioblastoma , 2003, Cancer.

[32]  P. Wust,et al.  Hyperthermia in combined treatment of cancer. , 2002, The Lancet Oncology.

[33]  P. Cornu,et al.  Brachytherapy of glioblastoma recurring in previously irradiated territory: predictive value of tumor volume. , 2002, International journal of radiation oncology, biology, physics.

[34]  A. Hart,et al.  Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial , 2000, The Lancet.

[35]  W. Hall,et al.  Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. , 1999, International journal of radiation oncology, biology, physics.

[36]  M J Gleason,et al.  Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  W. Curran,et al.  A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. , 1999, International journal of radiation oncology, biology, physics.

[38]  T L Phillips,et al.  Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme. , 1998, International journal of radiation oncology, biology, physics.

[39]  W. Curran,et al.  Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. , 1998, International journal of radiation oncology, biology, physics.

[40]  P. Wen,et al.  Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. , 1995, Neurosurgery.

[41]  R. Simon,et al.  Confidence intervals for reporting results of clinical trials. , 1986, Annals of internal medicine.